Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)
Sponsor: Dr. Md. Alimur Reza
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP). Eligible participants will be randomly assigned to one of two treatment arms. The first arm will receive faropenem at a dosage of 200 mg administered three times daily for a duration of seven days. The second arm will receive co-amoxiclav 625 mg, also three times daily, along with clarithromycin 500 mg, administered twice daily for seven days. All participants included in the study will undergo follow-up assessments over a period of four weeks. This research aims to provide valuable insights regarding the potential role of faropenem, thereby enhancing clinical outcomes and informing antibiotic stewardship in a region significantly burdened by CABP and characterized by limited treatment alternatives.
Official title: Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP): A Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2025-02-20
Completion Date
2025-12-01
Last Updated
2025-07-11
Healthy Volunteers
No
Interventions
Faropenem
Tab. Faropenem 200mg three times daily
Co-amoxiclav
Tab. Co-Amoxiclav 625mg three times daily
Clarithromycin 500 mg
Tab. Clarithromycin 500mg two times daily
Locations (2)
Popular Medical College & Hospital
Dhaka, Dhaka Division, Bangladesh
Shaheed Suhrawardy Medical College & Hospital
Dhaka, Dhaka Division, Bangladesh